← golden set
ABBV
AbbVie Inc.Healthcareanswer key
| field | SEC value | XBRL concept | printed on |
|---|---|---|---|
| Total revenue | $61.2B | RevenueFromContractWithCustomerExcludingAssessedTax | Net revenues |
| Operating income | $15.1B | OperatingIncomeLoss | Operating earnings |
| Net income attributable to the company | $4.2B | NetIncomeLoss | Net earnings attributable to AbbVie Inc. |
| Diluted EPS | $2.36 | EarningsPerShareDiluted | Diluted earnings per share attributable to AbbVie Inc. |
| Cash and cash equivalents | $5.2B | CashAndCashEquivalentsAtCarryingValue | Cash and equivalents |
| Total assets | $134.0B | Assets | Total assets · Total liabilities and equity |
| Total liabilities | - | not reported | not in this filing's XBRL |
| Total shareholders' equity attributable to the company | -$3.3B | StockholdersEquity | Total stockholders' equity (deficit) |
| Net cash from operating activities | $19.0B | NetCashProvidedByUsedInOperatingActivities | Cash flows from operating activities |
| Net cash from investing activities | -$6.6B | NetCashProvidedByUsedInInvestingActivities | Cash flows from investing activities |
| Net cash from financing activities | -$12.7B | NetCashProvidedByUsedInFinancingActivities | Cash flows from financing activities |
Income statement
table #80 · score 50.3 vs 30 runner-up · in millions| years ended December 31 (in millions, except per share data) | 2025 | 2024 | 2023 |
| Net revenues | 61,160 | 56,334 | 54,318 |
| Cost of products sold | 18,204 | 16,904 | 20,415 |
| Selling, general and administrative | 14,010 | 14,752 | 12,872 |
| Research and development | 9,096 | 12,791 | 7,675 |
| Acquired IPR&D and milestones | 5,016 | 2,757 | 778 |
| Other operating income | (241) | (7) | (179) |
| Total operating costs and expenses | 46,085 | 47,197 | 41,561 |
| Operating earnings | 15,075 | 9,137 | 12,757 |
| Interest expense, net | 2,627 | 2,160 | 1,684 |
| Net foreign exchange loss | 58 | 21 | 146 |
| Other expense, net | 5,793 | 3,240 | 4,677 |
| Earnings before income tax expense | 6,597 | 3,716 | 6,250 |
| Income tax expense (benefit) | 2,364 | (570) | 1,377 |
| Net earnings | 4,233 | 4,286 | 4,873 |
| Net earnings attributable to noncontrolling interest | 7 | 8 | 10 |
| Net earnings attributable to AbbVie Inc. | 4,226 | 4,278 | 4,863 |
| Per share data | |||
| Basic earnings per share attributable to AbbVie Inc. | 2.37 | 2.40 | 2.73 |
| Diluted earnings per share attributable to AbbVie Inc. | 2.36 | 2.39 | 2.72 |
| Weighted-average basic shares outstanding | 1,769 | 1,769 | 1,768 |
| Weighted-average diluted shares outstanding | 1,773 | 1,773 | 1,773 |
Balance sheet
table #84 · score 52.3 vs 20.5 runner-up · in millions| as of December 31 (in millions, except share data) | 2025 | 2024 |
| Assets | ||
| Current assets | ||
| Cash and equivalents | 5,229 | 5,524 |
| Short-term investments | 28 | 31 |
| Accounts receivable, net | 12,589 | 10,919 |
| Inventories | 4,951 | 4,181 |
| Prepaid expenses and other | 6,265 | 4,927 |
| Total current assets | 29,062 | 25,582 |
| Investments | 268 | 279 |
| Property and equipment, net | 5,628 | 5,134 |
| Intangible assets, net | 52,641 | 60,068 |
| Goodwill | 35,640 | 34,956 |
| Other assets | 10,721 | 9,142 |
| Total assets | 133,960 | 135,161 |
| Liabilities and Equity | ||
| Current liabilities | ||
| Short-term borrowings | 2,499 | - |
| Current portion of long-term debt and finance lease obligations | 6,056 | 6,804 |
| Accounts payable and accrued liabilities | 34,734 | 31,945 |
| Total current liabilities | 43,289 | 38,749 |
| Long-term debt and finance lease obligations | 58,941 | 60,340 |
| Deferred income taxes | 2,389 | 2,579 |
| Other long-term liabilities | 32,569 | 30,129 |
| Commitments and contingencies | ||
| Stockholders' equity (deficit) | ||
| Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,838,678,628 shares issued as of December 31, 2025 and 1,831,594,494 as of December 31, 2024 | 18 | 18 |
| Common stock held in treasury, at cost, 70,802,593 shares as of December 31, 2025 and 66,337,508 as of December 31, 2024 | (9,146) | (8,201) |
| Additional paid-in capital | 22,495 | 21,333 |
| Accumulated deficit | (15,493) | (7,900) |
| Accumulated other comprehensive loss | (1,144) | (1,925) |
| Total stockholders' equity (deficit) | (3,270) | 3,325 |
| Noncontrolling interest | 42 | 39 |
| Total equity (deficit) | (3,228) | 3,364 |
| Total liabilities and equity | 133,960 | 135,161 |
Cash flow statement
table #88 · score 55 vs 10 runner-up · in millions| years ended December 31 (in millions) (brackets denote cash outflows) | 2025 | 2024 | 2023 |
| Cash flows from operating activities | |||
| Net earnings | 4,233 | 4,286 | 4,873 |
| Adjustments to reconcile net earnings to net cash from operating activities: | |||
| Depreciation | 762 | 764 | 752 |
| Amortization of intangible assets | 7,377 | 7,622 | 7,946 |
| Deferred income taxes | (492) | (1,449) | (2,889) |
| Change in fair value of contingent consideration liabilities | 6,495 | 3,771 | 5,128 |
| Payments of contingent consideration liabilities | (2,865) | (1,995) | (870) |
| Stock-based compensation | 955 | 911 | 747 |
| Acquired IPR&D and milestones | 5,016 | 2,757 | 778 |
| Non-cash litigation reserve adjustments, net of cash payments | (933) | 508 | (443) |
| Impairment of intangible assets | 847 | 4,476 | 4,229 |
| Other, net | (3) | (63) | (225) |
| Changes in operating assets and liabilities, net of acquisitions: | |||
| Accounts receivable | (1,490) | 207 | 66 |
| Inventories | (234) | (319) | (417) |
| Prepaid expenses and other assets | (827) | 361 | (188) |
| Accounts payable and other liabilities | 951 | 177 | 3,840 |
| Income tax assets and liabilities, net | (762) | (3,208) | (488) |
| Cash flows from operating activities | 19,030 | 18,806 | 22,839 |
| Cash flows from investing activities | |||
| Acquisition of businesses, net of cash acquired | (204) | (17,493) | - |
| Other acquisitions and investments, net of cash acquired | (5,237) | (3,024) | (1,223) |
| Acquisitions of property and equipment | (1,214) | (974) | (777) |
| Purchases of investment securities | (35) | (73) | (77) |
| Sales and maturities of investment securities | 76 | 555 | 55 |
| Other, net | (29) | 189 | 13 |
| Cash flows from investing activities | (6,643) | (20,820) | (2,009) |
| Cash flows from financing activities | |||
| Net change in commercial paper borrowings with original maturities of three months or less | 499 | - | - |
| Proceeds from issuance of other short-term borrowings | 4,798 | 5,008 | - |
| Repayments of other short-term borrowings | (2,798) | (5,008) | - |
| Proceeds from issuance of long-term debt | 3,994 | 16,963 | - |
| Repayments of long-term debt and finance lease obligations | (6,797) | (9,613) | (4,149) |
| Debt issuance costs | (23) | (99) | (38) |
| Dividends paid | (11,657) | (11,025) | (10,539) |
| Purchases of treasury stock | (980) | (1,708) | (1,972) |
| Proceeds from the exercise of stock options | 172 | 214 | 180 |
| Payments of contingent consideration liabilities | - | - | (752) |
| Other, net | 68 | 57 | 48 |
| Cash flows from financing activities | (12,724) | (5,211) | (17,222) |
| Effect of exchange rate changes on cash and equivalents | 42 | (65) | 5 |
| Net change in cash and equivalents | (295) | (7,290) | 3,613 |
| Cash and equivalents, beginning of year | 5,524 | 12,814 | 9,201 |
| Cash and equivalents, end of year | 5,229 | 5,524 | 12,814 |
| Other supplemental information | |||
| Interest paid, net of portion capitalized | 3,002 | 2,811 | 2,469 |